XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. Its lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.
http://www.priceseries.com/trade/XTLB-XTL-Biopharmaceuticals-Ltd-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2017062120170713.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments